Dova Pharmaceuticals (DOVA) Upgraded by BidaskClub to Buy

Share on StockTwits

Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Several other brokerages also recently weighed in on DOVA. HC Wainwright started coverage on shares of Dova Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 price objective for the company. LADENBURG THALM/SH SH lifted their target price on shares of Dova Pharmaceuticals to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. cut shares of Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and cut their target price for the company from $34.00 to $20.00 in a report on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $29.50.

Shares of NASDAQ:DOVA opened at $9.34 on Thursday. The company has a market cap of $253.47 million, a PE ratio of -3.59 and a beta of 2.02. The company has a quick ratio of 5.51, a current ratio of 5.73 and a debt-to-equity ratio of 0.18. Dova Pharmaceuticals has a twelve month low of $5.62 and a twelve month high of $35.33.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.08. On average, equities research analysts forecast that Dova Pharmaceuticals will post -2.31 EPS for the current year.

In other Dova Pharmaceuticals news, Director Paul B. Manning bought 68,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were acquired at an average cost of $7.48 per share, with a total value of $508,640.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 55.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in DOVA. Geode Capital Management LLC increased its stake in Dova Pharmaceuticals by 8.1% in the 4th quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock valued at $1,184,000 after buying an additional 11,732 shares during the period. Squarepoint Ops LLC acquired a new position in Dova Pharmaceuticals in the 4th quarter valued at $137,000. Two Sigma Investments LP acquired a new position in Dova Pharmaceuticals in the 4th quarter valued at $136,000. Sphera Funds Management LTD. increased its stake in Dova Pharmaceuticals by 54.2% in the 4th quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock valued at $1,402,000 after buying an additional 65,000 shares during the period. Finally, Broadfin Capital LLC acquired a new position in Dova Pharmaceuticals in the 4th quarter valued at $2,667,000. 30.09% of the stock is currently owned by institutional investors and hedge funds.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Read More: Are all No-Load Funds Equal?

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DIMCOIN  Price Reaches $0.0010 on Top Exchanges
DIMCOIN Price Reaches $0.0010 on Top Exchanges
Contrasting Brown & Brown  & Its Rivals
Contrasting Brown & Brown & Its Rivals
Insperity Inc  Given Average Recommendation of “Buy” by Analysts
Insperity Inc Given Average Recommendation of “Buy” by Analysts
DCC plc  Given Average Rating of “Buy” by Analysts
DCC plc Given Average Rating of “Buy” by Analysts
Spectrum Management Group Inc. Sells 306 Shares of iShares S&P Small-Cap 600 Value ETF
Spectrum Management Group Inc. Sells 306 Shares of iShares S&P Small-Cap 600 Value ETF
Spectrum Management Group Inc. Has $473,000 Position in MAXIMUS, Inc.
Spectrum Management Group Inc. Has $473,000 Position in MAXIMUS, Inc.


© 2006-2019 Ticker Report